Screener
BridgeBio Pharma BBIO Prepaid & Other Current
Prepaid & Other Current at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Marketable securities | 60,295 | 17,363 |
| Accounts receivable, net | 205,226 | 139,444 |
| Inventories | 32,980 | 26,753 |
| Prepaid expenses and other current assets | 62,914 | 44,070 |
| Total current assets | 1,241,306 | 797,749 |
| Equity method investments | 61,529 | 79,972 |
| Property and equipment, net | 4,941 | 5,366 |
| Operating lease right-of-use assets | 17,226 | 8,149 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's prepaid & other current?
- BridgeBio Pharma (BBIO) reported prepaid & other current of $62.91M in Q1 2026.
- How has BridgeBio Pharma's prepaid & other current changed year-over-year?
- BridgeBio Pharma's prepaid & other current increased by 77.9% year-over-year, from $35.36M to $62.91M.
- What is the long-term trend for BridgeBio Pharma's prepaid & other current?
- Over 5 years (2020 to 2025), BridgeBio Pharma's prepaid & other current has grown at a 4.3% compound annual growth rate (CAGR), from $35.73M to $44.07M.
- What does prepaid & other current mean?
- Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.
Ask your AI about BridgeBio Pharma's prepaid & other current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude